Clinical experience with maprotilin and maprotilin/clomipramine infusions in resistant depression.
Maprotilin was given orally to 34 depressive patients for 3-6 weeks, or in daily morning i. v. infusions for 10-15 days to 23 patients, and in combined infusions with clomipramine to 32 patients. - At oral administration the effect was evident only after 10 days of treatment; most depressive symptoms improved. Maprotilin in infusions had a rapid onset of effect, being especially intensive on depressive mood and anxiety. The combined infusions of maprotilin and clomipramine affected an even wider range of symptoms. The factor anxiety somatization decreased significantly already after 7 days of treatment, more expressively after combined infusions. Side effects occurred only during the infusions.
D000284:Administration, Oral; D000328:Adult; D000873:Anthracenes / Q000627:therapeutic use*; D002997:Clomipramine / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008297:Male; D008376:Maprotiline / Q000627:therapeutic use*; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales
D000873:Anthracenes; D008376:Maprotiline; D002997:Clomipramine